1Texas Liver Institute, University of Texas Health Science Center, San Antonio.
2Institute of Liver Studies, Kings College Hospital, London, United Kingdom.
3Gastro One, Germantown, Tennessee.
4AbbVie Inc, North Chicago, Illinois.
In 247 subjects with hepatitis C virus genotype 1 infection treated with the interferon-free regimen of ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin, concordance of a sustained virologic response at 12 and 24 weeks supports the use of the earlier time point as a primary efficacy endpoint for trials of this interferon-free regimen.